Published in Clin Cancer Res on November 01, 2005
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer | NCT02549534
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) (2011) 3.33
Nanotechnology and cancer. Annu Rev Med (2008) 2.25
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64
Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev (2008) 1.43
A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer (2007) 1.34
Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia (2007) 1.29
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer (2008) 1.14
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs (2011) 1.08
Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med (2010) 1.07
Advances of cancer therapy by nanotechnology. Cancer Res Treat (2009) 1.01
Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate. Int J Nanomedicine (2010) 1.00
In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther (2008) 0.99
Targeted cytosolic delivery of cell-impermeable compounds by nanoparticle-mediated, light-triggered endosome disruption. Nano Lett (2010) 0.99
Clinical Translation of Nanomedicine. Chem Rev (2015) 0.93
A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models. Nat Commun (2015) 0.87
Silk-elastin-like protein biomaterials for the controlled delivery of therapeutics. Expert Opin Drug Deliv (2014) 0.84
Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics. Biomaterials (2013) 0.84
Clinically relevant anticancer polymer Paclitaxel therapeutics. Cancers (Basel) (2010) 0.84
Nanotechnologies for noninvasive measurement of drug release. Mol Pharm (2013) 0.81
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol (2008) 0.80
A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs. Int J Med Sci (2014) 0.76
PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3. Cancer Chemother Pharmacol (2015) 0.75
Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma. J Immunother (2017) 0.75
Procoagulant inhibitory properties of paclitaxel poliglumex. Int J Gen Med (2010) 0.75
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst (2004) 2.72
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (2008) 2.56
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res (2006) 2.45
Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol (2008) 1.93
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer (2008) 1.70
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol (2005) 1.69
Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clin Cancer Res (2007) 1.66
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood (2007) 1.54
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther (2002) 1.51
Wnt signalling regulates myogenic differentiation in the developing avian wing. Development (2003) 1.42
Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer (2003) 1.41
Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics (2006) 1.41
Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol (2006) 1.39
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer (2007) 1.38
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res (2005) 1.37
Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin (2014) 1.36
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs (2011) 1.34
Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res (2006) 1.33
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther (2009) 1.28
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res (2009) 1.25
Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol (2010) 1.25
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem (2008) 1.22
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer (2007) 1.21
Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation (2013) 1.19
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol (2009) 1.19
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol (2009) 1.15
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs (2005) 1.09
Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells. Cancer Res (2004) 1.09
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol (2002) 1.07
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res (2013) 1.03
Adjuvant therapy in colon cancer. Expert Rev Anticancer Ther (2012) 1.02
The candidate oncogene ZNF217 is frequently amplified in colon cancer. J Pathol (2004) 1.01
Wnt/Lef1 signaling acts via Pitx2 to regulate somite myogenesis. Dev Biol (2009) 1.01
Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer. J Clin Oncol (2006) 0.99
Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem (2003) 0.98
Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J Med Chem (2002) 0.98
Tbx1 regulation of myogenic differentiation in the limb and cranial mesoderm. Dev Dyn (2007) 0.97
Cell cycle perturbation and acquired 5-fluorouracil chemoresistance. Anticancer Res (2008) 0.96
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res (2009) 0.96
Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol (2011) 0.95
Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Lett (2009) 0.92
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst (2003) 0.91
Patient experiences following cardiothoracic surgery: an interview study. Eur J Cardiovasc Nurs (2005) 0.90
A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors. Clin Cancer Res (2004) 0.90
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol (2002) 0.90
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res (2002) 0.90
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res (2007) 0.89
Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol (2006) 0.88
Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma. J Immunol Methods (2009) 0.88
Choroidal metastasis from primary pulmonary leiomyosarcoma. Clin Experiment Ophthalmol (2011) 0.87
A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies. Clin Cancer Res (2008) 0.87
Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer (2012) 0.86
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenet Genomics (2011) 0.85
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J Med Chem (2004) 0.85
Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. Bioorg Med Chem Lett (2005) 0.85
Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer (2013) 0.83
Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease. Curr Med Res Opin (2010) 0.83
Pemetrexed safety and dosing strategy. Semin Oncol (2002) 0.83
Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncol Rep (2002) 0.83
Patient preferences for future care--how can Advance Care Planning become embedded into dementia care: a study protocol. BMC Geriatr (2010) 0.83
Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.83
Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett (2002) 0.83
A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. Cancer Chemother Pharmacol (2003) 0.82
A phase II study of caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulation. Invest New Drugs (2002) 0.81
Isolation of satellite cells from single muscle fibers from young, aged, or dystrophic muscles. Methods Mol Biol (2012) 0.81
Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. Clin Cancer Res (2005) 0.80
Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis. J Clin Oncol (2013) 0.79
Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible. Exp Dermatol (2005) 0.79
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorg Med Chem Lett (2003) 0.79
Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. Cancer Chemother Pharmacol (2014) 0.79
Isolated Meningeal Recurrence of Transitional Cell Carcinoma of the Bladder. Case Rep Oncol (2010) 0.79
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. Cancer Chemother Pharmacol (2014) 0.78
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Clin Colorectal Cancer (2013) 0.78
Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal. Pharmacoeconomics (2013) 0.78
Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein. J Med Chem (2011) 0.77
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide. Br J Clin Pharmacol (2002) 0.76
Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified. BMJ (2002) 0.75
Diagnostic Biomarkers in Women With Suspected Preeclampsia in a Prospective Multicenter Study. Obstet Gynecol (2016) 0.75
Dosing of cancer patients with low or absent renal function. Therapie (2007) 0.75
Roles, relationships, perils and values: development of a pathway between practice development and evaluation research. Qual Prim Care (2008) 0.75
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer (2016) 0.75
Abortion rights of minors. Women's Rights Law Report (1983) 0.75
Low-threshold laser medium utilizing semiconductor nanoshell quantum dots. Nanoscale (2020) 0.75
Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). Anticancer Drugs (2004) 0.75